MX340846B - Composición de nitazoxanida mejorada y proceso para prepararla. - Google Patents

Composición de nitazoxanida mejorada y proceso para prepararla.

Info

Publication number
MX340846B
MX340846B MX2014008975A MX2014008975A MX340846B MX 340846 B MX340846 B MX 340846B MX 2014008975 A MX2014008975 A MX 2014008975A MX 2014008975 A MX2014008975 A MX 2014008975A MX 340846 B MX340846 B MX 340846B
Authority
MX
Mexico
Prior art keywords
nitazoxanide
composition
granules
preparation
improved
Prior art date
Application number
MX2014008975A
Other languages
English (en)
Other versions
MX2014008975A (es
Inventor
Esteban Alejandro Fiore
Original Assignee
Rhein Siegfried Sa De Cv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhein Siegfried Sa De Cv filed Critical Rhein Siegfried Sa De Cv
Publication of MX2014008975A publication Critical patent/MX2014008975A/es
Publication of MX340846B publication Critical patent/MX340846B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

La presente invención se relaciona a una composición farmacéutica de administración oral de nitazoxanida útil para el tratamiento de infecciones parasitarias intestinales en la forma de gránulos para suspensión, en donde dicha composición contiene: (a) una fracción de liberación inmediata compuesta por gránulos sin recubrimiento o polvo sin granular de nitazoxanida; y (b) una fracción de liberación pH-dependiente formada por gránulos de nitazoxanida recubiertos por uno o más polímeros de solubilidad pH-dependiente.
MX2014008975A 2012-01-27 2012-01-27 Composición de nitazoxanida mejorada y proceso para prepararla. MX340846B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2012/050380 WO2013110975A1 (es) 2012-01-27 2012-01-27 Composición de nitazoxanida mejorada y proceso para prepararla

Publications (2)

Publication Number Publication Date
MX2014008975A MX2014008975A (es) 2014-11-10
MX340846B true MX340846B (es) 2016-07-28

Family

ID=48872931

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014008975A MX340846B (es) 2012-01-27 2012-01-27 Composición de nitazoxanida mejorada y proceso para prepararla.

Country Status (10)

Country Link
US (1) US9498441B2 (es)
EP (1) EP2808019B1 (es)
AR (1) AR089764A1 (es)
BR (1) BR112014018149B1 (es)
CL (1) CL2014001983A1 (es)
CR (1) CR20140351A (es)
MX (1) MX340846B (es)
NI (1) NI201400082A (es)
UY (1) UY34457A (es)
WO (1) WO2013110975A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019241376A1 (en) 2018-06-14 2019-12-19 The Trustees Of Columbia University In The City Of New York Treatment of cognitive disorders using nitazoxanide (ntz), nitazoxanide (ntz) analogs, and metabolites thereof
CN116983273A (zh) * 2023-08-02 2023-11-03 海南慧谷药业有限公司 一种盐酸文拉法辛缓释制剂及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657267A (en) 1969-06-20 1972-04-18 Janssen Pharmaceutica Nv Benzimidazole carbamates
GB1437800A (en) 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
JPS517116A (en) * 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
US5387598A (en) 1994-04-13 1995-02-07 Rossignol; Jean-Francois Composition and galenic formulation suitable for combatting affections of the lower abdomen
US5968961A (en) 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
KR100426657B1 (ko) 1997-05-07 2004-04-13 로마크 레버러토리즈, 엘.씨. 티족사나이드 및 니타족사나이드의 약제학적 조성물
US6132461A (en) 1998-03-27 2000-10-17 Intratherapeutics, Inc. Stent with dual support structure
US20040253323A1 (en) * 2003-06-11 2004-12-16 Giles Brian C. Ionic cancer therapy and methods for using same in the treatment of tumors and metastasis
JP4790620B2 (ja) * 2003-11-27 2011-10-12 グリフィス ユニバーシティ 新規な鎮痛性化合物，これを含有する抽出物及びその製造方法
US20050171169A1 (en) 2004-02-02 2005-08-04 Rossignol Jean F. Combination chemotherapy for helminth infections
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
PT1971588E (pt) * 2005-12-23 2012-10-16 Qbiotics Ltd Derivados de tiglien-3-ona
AP2907A (en) 2006-01-09 2014-05-31 Romark Lab Lc Viral hepatitis treatment
US20080299188A1 (en) 2007-05-14 2008-12-04 Pfizer Inc. Controlled release dosage forms combining immediate release and sustainted release of low-solubility drug
EP2374460A4 (en) 2008-12-12 2013-08-21 Rhein Siegfried Sa De Cv SILDENAFIL COMPOSITION WITH PULSED RELEASE AND METHOD FOR PRODUCING THIS COMPOSITION
EP2395840B1 (en) 2009-02-13 2020-04-15 Romark Laboratories, L.C. Controlled release pharmaceutical formulations of nitazoxanide

Also Published As

Publication number Publication date
US9498441B2 (en) 2016-11-22
BR112014018149A2 (es) 2017-06-20
BR112014018149B1 (pt) 2020-09-29
CL2014001983A1 (es) 2015-03-06
US20150064262A1 (en) 2015-03-05
AR089764A1 (es) 2014-09-17
UY34457A (es) 2013-09-02
BR112014018149A8 (pt) 2017-07-11
EP2808019A1 (en) 2014-12-03
NI201400082A (es) 2017-03-13
MX2014008975A (es) 2014-11-10
WO2013110975A1 (es) 2013-08-01
EP2808019A4 (en) 2015-06-10
EP2808019B1 (en) 2019-09-25
CR20140351A (es) 2014-11-05

Similar Documents

Publication Publication Date Title
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
MX363347B (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
WO2012174158A3 (en) Administration of benzodiazepine
MX2013001677A (es) Formulaciones estables de linaclotida.
HK1206028A1 (en) Phenicol antibacterials
WO2014144295A8 (en) Ceftolozane antibiotic compositions
IL247239A0 (en) Complexes of sirolimus and its derivatives, a process for their preparation and pharmaceutical preparations containing them
WO2013134534A3 (en) Solid state forms of cabazitaxel and processes for preparation thereof
WO2016011049A3 (en) Compositions and methods for disease treatment using nanoparticle delivered compounds
MY165075A (en) Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
EP3284743A4 (en) Heterocyclic-imidazole compounds, pharmaceutical compositions thereof, preparation method therefor and use thereof
MX364946B (es) Sistema adyuvante mejorado para la administración de vacunas orales.
IN2014CH00840A (es)
WO2015001541A3 (en) Pharmaceutical film composition
EP3290037A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
EA201400444A1 (ru) Производные 2-оксопиперидинила
IL272806A (en) The history of boronic acid, its preparation and pharmaceutical preparations containing it
PH12013500210A1 (en) Highly crystalline valsartan
WO2016063289A3 (en) Pharmaceutical tablet compositions comprising rifaximin
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
WO2016197042A8 (en) Modified or targeted release formulations of linaclotide
MX340846B (es) Composición de nitazoxanida mejorada y proceso para prepararla.
WO2014128728A3 (en) Solid forms of cabazitaxel and processes for preparation thereof
WO2014122671A3 (en) Solid oral compositions of saxagliptin

Legal Events

Date Code Title Description
FG Grant or registration